Effect of "DXB-2030," a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism

The objective of the present study was to evaluate "DXB-2030," a polyherbal combination of Trigonella foenum-graecum, Aloe vera, Sphaeranthus indicus, Nardostachys jatamansi, and Symplocos racemosa extracts in an experimental model of testosterone propionate (TP), induced polycystic ovary...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Mohammed Azeemuddin (Yazar), Suryakanth D. Anturlikar (Yazar), Mallappa Onkaramurthy (Yazar), Mirza R. Baig (Yazar), Basti K. Ashok (Yazar), Raghavendra P. Rao (Yazar), Mohamed Rafiq (Yazar), Paramesh Rangesh (Yazar)
Materyal Türü: Kitap
Baskı/Yayın Bilgisi: Hindawi Limited, 2019-01-01T00:00:00Z.
Konular:
Online Erişim:Connect to this object online.
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_977cec7a82cc4a329c4af2fd7bfde3c6
042 |a dc 
100 1 0 |a Mohammed Azeemuddin  |e author 
700 1 0 |a Suryakanth D. Anturlikar  |e author 
700 1 0 |a Mallappa Onkaramurthy  |e author 
700 1 0 |a Mirza R. Baig  |e author 
700 1 0 |a Basti K. Ashok  |e author 
700 1 0 |a Raghavendra P. Rao  |e author 
700 1 0 |a Mohamed Rafiq  |e author 
700 1 0 |a Paramesh Rangesh  |e author 
245 0 0 |a Effect of "DXB-2030," a Polyherbal Formulation, on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism 
260 |b Hindawi Limited,   |c 2019-01-01T00:00:00Z. 
500 |a 1687-6334 
500 |a 1687-6342 
500 |a 10.1155/2019/8272850 
520 |a The objective of the present study was to evaluate "DXB-2030," a polyherbal combination of Trigonella foenum-graecum, Aloe vera, Sphaeranthus indicus, Nardostachys jatamansi, and Symplocos racemosa extracts in an experimental model of testosterone propionate (TP), induced polycystic ovary syndrome (PCOS) in female rats. Thirty animals were divided into 3 groups of 10 each; group 1 served as normal control; group 2 was administered with TP and served as positive control; along with TP, group 3 was treated with "DXB-2030" at a dose of 100 mg/kg p.o., for 60 days. At the end of the study period, the animals were subjected for the estimation of serum testosterone levels, oral glucose tolerance test (OGTT), weight of the ovaries, estrous cycle, and histopathological evaluation. An in vitro assay on GLUT4 expression was carried out to understand the effect of "DXB-2030" on insulin resistance. Results showed that treatment with "DXB-2030" reversed the TP-induced changes by increasing the GLUT4 expression and decreasing the body weight, testosterone levels, AUC of glucose in OGTT, and the cystic follicles of the ovaries, thus indicating its beneficial effect in PCOS by ameliorating the metabolic dysfunction and reproductive impairment, which are the pathophysiological conditions associated with PCOS. From the results obtained, it can be concluded that "DXB-2030" was effective in the management of experimental PCOS and hence may be recommended in the treatment of PCOS. 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Advances in Pharmacological Sciences, Vol 2019 (2019) 
787 0 |n http://dx.doi.org/10.1155/2019/8272850 
787 0 |n https://doaj.org/toc/1687-6334 
787 0 |n https://doaj.org/toc/1687-6342 
856 4 1 |u https://doaj.org/article/977cec7a82cc4a329c4af2fd7bfde3c6  |z Connect to this object online.